At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 183 enrolled
Drug / intervention
VIB4920 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Randomized, Double-blind, Placebo-controlled, Proof of Concept Study to Evaluate the Efficacy and Safety of VIB4920 in Subjects With Sjögren's Syndrome (SS)
In Brief
A Phase 2 clinical trial evaluating VIB4920 and Placebo for Sjögren's Syndrome. Completed, enrolled 183 participants across 62 sites in 12 countries.
Detailed Summary
The purpose of the study is to evaluate the efficacy, safety, and tolerability of VIB4920 (formerly MEDI4920) in adult participants with Sjögren's Syndrome (SS).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSjögren's Syndrome
CountriesArgentina, France, Hungary, India, Italy, Mexico, Peru, Poland, South Korea, Taiwan, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedOct 2019
Enrollment StartDec 2019
Primary CompletionSep 2022
Study CompletionMar 2023
TodayJul 2026
First PostedOct 16, 2019
Enrollment StartDec 9, 2019
Primary CompletionSep 1, 2022
Study CompletionMar 10, 2023
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 6.7 years ago
Interventions
VIB4920drug
Intravenous Dose 1.
Placebodrug
Intravenous dose matched to VIB4920.